Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker CRL
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 22, 2026 | James C. Foster Director | CRL Charles River Laboratories International, Inc. | Sale | 24,042 | $350.00 | $8.4M Sale | Form 4 ↗ |
| Oct 21, 2026 | Shannon M. Parisotto CEVP, Disc & Safety Assessment | CRL Charles River Laboratories International, Inc. | Sale | 2,156 | $344.41 | $742.5K Sale | Form 4 ↗ |
| Aug 25, 2026 | James C. Foster Director | CRL Charles River Laboratories International, Inc. | Sale | 33,561 | $300.00 | $10.1M Sale | Form 4 ↗ |
| Aug 19, 2026 | Shannon M. Parisotto CEVP, Disc & Safety Assessment | CRL Charles River Laboratories International, Inc. | Sale | 2,039 | $294.12 | $599.7K Sale | Form 4 ↗ |
| Aug 18, 2026 | Nancy C. Andrews Director | CRL Charles River Laboratories International, Inc. | Sale | 573 | $285.24 | $163.4K Sale | Form 4 ↗ |
| Aug 11, 2026 | Birgit Girshick Chief Executive Officer, Director | CRL Charles River Laboratories International, Inc. | Sale | 6,500 | $279.90 | $1.8M Sale | Form 4 ↗ |
| Aug 11, 2026 | Shannon M. Parisotto CEVP, Disc & Safety Assessment | CRL Charles River Laboratories International, Inc. | Sale | 3,714 | $279.66 | $1.0M Sale | Form 4 ↗ |
| Aug 10, 2026 | James C. Foster Director | CRL Charles River Laboratories International, Inc. | Sale | 28,733 | $275.00 | $7.9M Sale | Form 4 ↗ |
| Aug 6, 2026 | Michael Gunnar Knell SVP, Finance and CAO | CRL Charles River Laboratories International, Inc. | Sale | 736 | $258.53 | $190.3K Sale | Form 4 ↗ |
| Aug 6, 2026 | Michael Gunnar Knell SVP, Finance and CAO | CRL Charles River Laboratories International, Inc. | Sale | 1,205 | $258.53 | $311.5K Sale | Form 4 ↗ |
| Aug 6, 2026 | Michael Gunnar Knell SVP, Finance and CAO | CRL Charles River Laboratories International, Inc. | Sale | 404 | $258.53 | $104.4K Sale | Form 4 ↗ |
| Aug 6, 2026 | Michael Gunnar Knell SVP, Finance and CAO | CRL Charles River Laboratories International, Inc. | Sale | 482 | $265.17 | $127.8K Sale | Form 4 ↗ |
| Aug 6, 2026 | Michael Gunnar Knell SVP, Finance and CAO | CRL Charles River Laboratories International, Inc. | Sale | 620 | $263.94 | $163.6K Sale | Form 4 ↗ |
| Aug 6, 2026 | Michael Gunnar Knell SVP, Finance and CAO | CRL Charles River Laboratories International, Inc. | Sale | 213 | $262.37 | $55.9K Sale | Form 4 ↗ |
| Aug 6, 2026 | Michael Gunnar Knell SVP, Finance and CAO | CRL Charles River Laboratories International, Inc. | Sale | 810 | $261.45 | $211.8K Sale | Form 4 ↗ |
| Aug 6, 2026 | Michael Gunnar Knell SVP, Finance and CAO | CRL Charles River Laboratories International, Inc. | Sale | 901 | $260.63 | $234.8K Sale | Form 4 ↗ |
| Aug 6, 2026 | Michael Gunnar Knell SVP, Finance and CAO | CRL Charles River Laboratories International, Inc. | Sale | 1,274 | $259.07 | $330.1K Sale | Form 4 ↗ |
| Aug 6, 2026 | Victoria L. Creamer EVP & Chief People Officer | CRL Charles River Laboratories International, Inc. | Sale | 4,179 | $259.16 | $1.1M Sale | Form 4 ↗ |
| Aug 5, 2026 | Shannon M. Parisotto CEVP, Disc & Safety Assessment | CRL Charles River Laboratories International, Inc. | Sale | 5,046 | $263.00 | $1.3M Sale | Form 4 ↗ |
| Jun 29, 2026 | James C. Foster Director | CRL Charles River Laboratories International, Inc. | Sale | 75,000 | $225.00 | $16.9M Sale | Form 4 ↗ |
| Mar 3, 2026 | Joseph W. LaPlume EVP, Corp Strategy & Develop | CRL Charles River Laboratories International, Inc. | Buy | 25 | $174.54 | $4,364 Buy | Form 4 ↗ |
| Aug 22, 2025 | Joseph W. LaPlume EVP, Corp Strategy & Develop | CRL Charles River Laboratories International, Inc. | Sale | 400 | $163.72 | $65.5K Sale | Form 4 ↗ |
| Aug 18, 2025 | Joseph W. LaPlume EVP, Corp Strategy & Develop | CRL Charles River Laboratories International, Inc. | Sale | 800 | $157.60 | $126.1K Sale | Form 4 ↗ |
| Aug 7, 2025 | Joseph W. LaPlume EVP, Corp Strategy & Develop | CRL Charles River Laboratories International, Inc. | Sale | 400 | $150.04 | $60.0K Sale | Form 4 ↗ |
| May 15, 2025 | George Massaro Director | CRL Charles River Laboratories International, Inc. | Sale | 24 | $139.05 | $3,337 Sale | Form 4 ↗ |
| May 15, 2025 | George Massaro Director | CRL Charles River Laboratories International, Inc. | Sale | 81 | $137.68 | $11.2K Sale | Form 4 ↗ |
| May 15, 2025 | George Massaro Director | CRL Charles River Laboratories International, Inc. | Sale | 35 | $136.32 | $4,771 Sale | Form 4 ↗ |
| May 14, 2025 | George Massaro Director | CRL Charles River Laboratories International, Inc. | Sale | 7 | $145.54 | $1,019 Sale | Form 4 ↗ |
| May 14, 2025 | George Massaro Director | CRL Charles River Laboratories International, Inc. | Sale | 7 | $143.77 | $1,006 Sale | Form 4 ↗ |
| May 14, 2025 | George Massaro Director | CRL Charles River Laboratories International, Inc. | Sale | 14 | $141.85 | $1,986 Sale | Form 4 ↗ |
| May 14, 2025 | George Massaro Director | CRL Charles River Laboratories International, Inc. | Sale | 21 | $140.78 | $2,956 Sale | Form 4 ↗ |
| May 14, 2025 | George Massaro Director | CRL Charles River Laboratories International, Inc. | Sale | 91 | $139.95 | $12.7K Sale | Form 4 ↗ |
| May 13, 2025 | Joseph W. LaPlume EVP, Corp Strategy & Develop | CRL Charles River Laboratories International, Inc. | Sale | 500 | $145.41 | $72.7K Sale | Form 4 ↗ |
| Feb 20, 2025 | James C. Foster Chairman, President and CEO, Director | CRL Charles River Laboratories International, Inc. | Buy | 6,075 | $165.01 | $1.0M Buy | Form 4 ↗ |
| Feb 20, 2025 | Birgit Girshick Corporate Executive VP & COO | CRL Charles River Laboratories International, Inc. | Buy | 1,514 | $164.63 | $249.2K Buy | Form 4 ↗ |
| Feb 20, 2025 | Joseph W. LaPlume EVP, Corp Strategy & Develop | CRL Charles River Laboratories International, Inc. | Sale | 4,400 | $162.50 | $715.0K Sale | Form 4 ↗ |
| Nov 7, 2024 | Richard F. Wallman Director | CRL Charles River Laboratories International, Inc. | Sale | 1,000 | $216.50 | $216.5K Sale | Form 4 ↗ |
| Nov 7, 2024 | Richard F. Wallman Director | CRL Charles River Laboratories International, Inc. | Sale | 3,250 | $216.50 | $703.6K Sale | Form 4 ↗ |
| Nov 7, 2024 | Richard F. Wallman Director | CRL Charles River Laboratories International, Inc. | Sale | 3,371 | $215.75 | $727.3K Sale | Form 4 ↗ |
39 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:33 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances